Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac

These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. This document has been updated: version 15 March 2022.